Contact usWorldwide
HomeAbout RosettaOur ScienceCareers

Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co. Inc., develops and implements technologies that will improve drug discovery. Read More
News
» Genomics & Proteomics article, "RNA Transcript Jumble Adds Splice to Life."


» Seattle Times article, "Local researchers link 3 new genes to obesity"


» ScienCentral News: "Tiny Genes, Big Role"


» Seattle Times article, "Rosetta's thriving as Merck subsidiary"


» Nature article, "Genetics of Gene Expression Surveyed in Maize, Mouse and Man", details the work being done by Rosetta Inpharmatics in collaboration with UCLA and others to identify the different subtypes of obesity and the genetic differences of the individual subtypes.


» U.S. News & World Report article, "Cracking The Cancer Code," includes an interview with Rosetta Inpharmatics' President, Stephen H. Friend, M.D., Ph.D.


» Rosetta Inpharmatics' President, Stephen H. Friend, M.D., Ph.D., featured in New York Times article, Telling the Threatening Tumors from the Harmless Ones.

Printer Friendly Page
 

About Rosetta

Rosetta Inpharmatics was founded in 1996 to design and implement DNA microarray gene expression technologies...Learn more

Our Science

Rosetta Inpharmatics' scientific foundation was built on gene expression research....Learn more

Careers

We are constantly in search of new graduates, academic researchers and experienced professionals in all functional disciplines...Learn more

Post-Doctorate

For information on
Post-Doctorate Opportunities...Click here
 
Site Map Privacy Policy - Opens New Window Trademarks - Opens New Window Terms of Use - Opens New Window Copyright © 2004-2007 Rosetta Inpharmatics LLC. - Opens New Window Merck & Co., Inc. (USA) - Opens New Window